Jones was honored for international collaborative research on neonatal opioid withdrawal.

Dr. Hendree Jones

Hendrée E Jones, Ph.D., executive director of the UNC Horizons Program, has been selected as a 2015 National Institute on Drug Abuse (NIDA) International Program Awards of Excellence winner for her international efforts to advance drug abuse research and training.

The NIDA International Program recognized Dr. Jones along with Gabriele Fischer, M.D., from the Medical University of Vienna, Austria, together for Excellence in International Collaborative Research. The 2015 Awards of Excellence winners were announced on June 13 at the 20th annual NIDA International Forum in Phoenix, Arizona.

Dr. Jones led the multi-site clinical trial of Maternal Opioid Treatment: Human Experimental Research—the MOTHER study—and Dr. Fischer led the study’s Austrian site. The MOTHER study demonstrated that buprenorphine reduced the symptoms of neonatal opioid withdrawal when compared with methadone, and that the medication was a safe and effective treatment for opioid dependence during pregnancy.

“Dr. Jones is an outstanding leader in the substance abuse community,” said Steven W. Gust, Ph.D., director of the NIDA International Program. “She and her colleagues have provided the scientific evidence of the benefits buprenorphine provides to mothers who are addicted to opioids and their infants.”

Dr. Jones leads or is involved in projects focused on improving the lives of children, women and families in Afghanistan, the Southern Cone, the Republic of Georgia, South Africa, as well as the United States. She retains an adjunct faculty position at Johns Hopkins University as a professor in the Department of Psychiatry and Department of Gynecology and Obstetrics.

Additional information is available here. NIDA is part of the National Institutes of Health, the principal biomedical and behavioral research agency of the U.S. Government and a component of the U.S. Department of Health and Human Services.